Announced Tue, 21 Jul · 19:30 IST
Anthem Biosciences Q1FY27: Revenue falls 22.6% YoY to Rs 4,182 Cr
ANTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-1.5%1-day move
₹794.00
prior close
₹750.60
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.8+1.4-0.4+0.1-1.5-3.1-0.6-1.3——————
Up moveDown movePending
AI summary
Anthem Biosciences Q1FY27 consolidated revenue fell 22.6% YoY to Rs 4,182 Mn from Rs 5,402 Mn. EBITDA was Rs 1,755 Mn at 39.6% margins, down 18.1% YoY. PAT declined 11.7% YoY to Rs 1,199 Mn at 27.1% margins. CRDMO revenue dropped 24.7% YoY to Rs 3,408 Mn. Management attributed the decline to timing shifts in customer deliveries and expects stronger performance in the second half of FY27.
Likely market impact
Sharp YoY revenue and profit decline on delivery timing issues. Management guides for H2 recovery, but near-term stock sentiment may remain cautious.